Marchet A, Mocellin S, Ambrosi A, de Manzoni G, Di Leo A, Marrelli D, Roviello F, Morgagni P, Saragoni L, Natalini G, De Santis F, Baiocchi L, Coniglio A, Nitti D
Clinica Chirurgica II, University of Padova, Padova, Italy.
Eur J Surg Oncol. 2008 Feb;34(2):159-65. doi: 10.1016/j.ejso.2007.04.018. Epub 2007 Jun 13.
The proportion between metastatic and examined lymph nodes (N-ratio) has been proposed as an independent prognostic factor in patients with gastric cancer. In the present work we validated the reliability of N-ratio in a large, multicenter series.
We retrospectively reviewed the data of 1853 patients who underwent radical resection for gastric carcinoma. Survival of patients with >15 (Group-1, n=1421) and those with < or =15 (Group-2, n=432) lymph nodes examined was separately analyzed in order to evaluate the influence of lymph node dissection on disease staging. N-ratio categories (N-ratio 0, 0%; N-ratio 1, 1-9%; N-ratio 2, 10-25%; N-ratio 3, >25%) were determined by the best cut-off approach.
At multivariate analysis, N-ratio (but not TNM N-category) was retained as an independent prognostic factor both in Group-1 and Group-2 (HR for N-ratio 1, N-ratio 2 and N-ratio 3=1.67, 2.96 and 6.59, and 1.56, 2.68 and 4.28, respectively). After a median follow-up of 45.5 months, the 5-year overall survival rates of TNM N0, N1 and N2 patients were significantly different in Group-1 vs Group-2. This was not the case when adopting the N-ratio classification, suggesting that a low number of excised lymph nodes can lead to patients being understaged using the N-category, but not N-ratio. Moreover, N-ratio identified subsets of patients with significantly different survival rates within TNM N1 and N2 categories in both groups.
N-ratio is a simple and reproducible prognostic tool that can stratify patients with gastric cancer, including those cases with limited lymph node dissection. These data support the rationale to propose the implementation of N-ratio into the current TNM staging system.
转移淋巴结与检查淋巴结的比例(N 比值)已被提出作为胃癌患者的独立预后因素。在本研究中,我们在一个大型多中心系列研究中验证了 N 比值的可靠性。
我们回顾性分析了 1853 例行胃癌根治性切除术患者的数据。分别分析检查淋巴结数>15 个的患者(第 1 组,n = 1421)和检查淋巴结数≤15 个的患者(第 2 组,n = 432)的生存情况,以评估淋巴结清扫对疾病分期的影响。N 比值类别(N 比值 0,0%;N 比值 1,1 - 9%;N 比值 2,10 - 25%;N 比值 3,>25%)通过最佳截断点法确定。
在多因素分析中,N 比值(而非 TNM N 分期类别)在第 1 组和第 2 组中均被保留为独立预后因素(N 比值 1、N 比值 2 和 N 比值 3 的风险比分别为 1.67、2.96 和 6.59,以及 1.56、2.68 和 4.28)。中位随访 45.5 个月后,第 1 组与第 2 组中 TNM N0、N1 和 N2 患者的 5 年总生存率存在显著差异。采用 N 比值分类时情况并非如此,这表明切除淋巴结数量较少会导致使用 N 分期类别对患者分期不足,但使用 N 比值则不会。此外,N 比值在两组的 TNM N1 和 N2 类别中均识别出了生存率显著不同的患者亚组。
N 比值是一种简单且可重复的预后工具,可对胃癌患者进行分层,包括那些淋巴结清扫有限的病例。这些数据支持将 N 比值纳入当前 TNM 分期系统的合理性。